Vitamin C, VIP (vasoactive intestinal polypeptide) and gastrin in the serum of COPD patients in stable state and during exacerbation Source: Eur Respir J 2002; 20: Suppl. 38, 259s Year: 2002
Serum level of VIP (vasoactive intestinal polypeptide) in patients with COPD in stable state and during exacerbation Source: Eur Respir J 2001; 18: Suppl. 33, 483s Year: 2001
Concentration of vasoactive intestinal peptide (VIP) and substance P (SP) in bronchi of patients with mild to moderate bronchial asthma Source: Eur Respir J 2005; 26: Suppl. 49, 583s Year: 2005
Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis Source: Eur Respir J 2004; 24: 958-963 Year: 2004
Vasoactive intestinal peptide receptor 2 (VIPR2) in central airways of smokers Source: Eur Respir J 2002; 20: Suppl. 38, 88s Year: 2002
Distribution of vasoactive intestinal peptide( VIP)- and substance P (SP)- containing innervation in bronchi of patients with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004
Serum surfactant protein D (SP-D) is a lung derived biomarker for COPD that is responsive to treatment with oral corticosteroids Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD Year: 2008
Serum surfactant protein D (SPD) and response to the combined therapy in patients (pts) with stable COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012
Inhaled vasoactive intestinal peptide exerts immune-regulatory effects in patients with sarcoidosis Source: Annual Congress 2009 - From genetics to clinics in diffuse parenchymal lung diseases Year: 2009
Vasoactive intestinal peptide (VIP) for treatment of COPD: improvement in spiroergometry and 6 minute walking distance Source: Eur Respir J 2006; 28: Suppl. 50, 430s Year: 2006
Serum vitamin C level in patients with acute pneumonia and in COPD patients before and after therapy Source: Eur Respir J 2006; 28: Suppl. 50, 38s Year: 2006
Vitamin D and cathelicidin serum levels in children with infection induced asthma Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017
Vitamin D (25OHD3) and parathyroid hormone (PTH) status in patients with COPD Source: Annual Congress 2007 - Managing COPD in primary care Year: 2007
Expression vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets Source: Eur Respir J 2006; 28: Suppl. 50, 659s Year: 2006
Sputum Vitamin D binding protein (VDBP) GC1S/1S genotype predicts airway obstruction: a prospective study in smokers with COPD Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases Year: 2020
Inhaled vasoactive intestinal peptide (VIP) improves pulmonary gas exchange in acute respiratory distress syndrome (ARDS) - a case report Source: Eur Respir J 2003; 22: Suppl. 45, 70s Year: 2003
The relationship between respiratory muscle dysfunction and serum vitamin D level in COPD patients Source: Virtual Congress 2021 – Lung function evaluation and assessment of airway diseases Year: 2021
Vasoactive intestinal peptide-receptor regulation in monocytes derived from COPD patients Source: Annual Congress 2007 - Cell biology of asthma and COPD Year: 2007
The effects of endogenous and exogenous vitamin D on the rate of mature elastin degradation in COPD patients Source: International Congress 2016 – New signalling pathways in COPD Year: 2016
Inhalation of vasoactive intestinal peptide in pulmonary hypertension Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008